Laws Edward R, Sheehan Jason P, Sheehan Jonas M, Jagnathan Jay, Jane John A, Oskouian Rod
University of Virginia, Charlottesville, VA 22908, USA.
J Neurooncol. 2004 Aug-Sep;69(1-3):257-72. doi: 10.1023/b:neon.0000041887.51906.b7.
Pituitary adenomas are very common neoplasms and represent between 10 and 20% of all primary brain tumors. Historically, the treatment armamentarium for pituitary adenomas included medical management, microsurgery, and fractionated radiotherapy. More recently, radiosurgery has emerged as a viable treatment option. The goal of this research is to define accurately the efficacy, safety, and role of radiosurgery for treatment of pituitary adenomas.
Medical literature databases from 1965 to 2003 were searched for articles pertaining to pituitary adenomas and stereotactic radiosurgery. Each study was evaluated for the number of patients, radiosurgical parameters (e.g. tumor margin dose), length of follow-up, tumor growth control rate, complications, and rate of hormonal normalization in the case of functioning adenomas.
A total of 34 published studies including 1567 patients were reviewed. Radiosurgery offers a tumor growth control rate of approximately 90%. The reported rates of hormonal normalization for functioning adenomas vary substantially. This range is in part due to widespread differences in endocrinological criteria utilized for post-radiosurgical assessment. Thus far, the risks of radiation induced neoplasia and cerebral vasculopathy associated with radiosurgery appear to be lower than for fractionated radiation therapy. The incidence of other serious complications following radiosurgery is quite low.
Although surgical resection typically is the primary treatment modality, stereotactic radiosurgery offers safe and effective treatment for recurrent or residual pituitary adenomas. In rare instances, radiosurgery may be the best initial treatment for patients with pituitary adenomas. Refinements in the radiosurgical technique will likely lead to improved outcomes.
垂体腺瘤是非常常见的肿瘤,占所有原发性脑肿瘤的10%至20%。从历史上看,垂体腺瘤的治疗手段包括药物治疗、显微手术和分次放射治疗。最近,放射外科已成为一种可行的治疗选择。本研究的目的是准确界定放射外科治疗垂体腺瘤的疗效、安全性及作用。
检索1965年至2003年医学文献数据库中与垂体腺瘤和立体定向放射外科相关的文章。对每项研究评估患者数量、放射外科参数(如肿瘤边缘剂量)、随访时间、肿瘤生长控制率、并发症以及功能性腺瘤患者的激素正常化率。
共回顾了34项已发表的研究,涉及1567例患者。放射外科的肿瘤生长控制率约为90%。报道的功能性腺瘤激素正常化率差异很大。这一范围部分归因于放射外科术后评估所采用的内分泌学标准存在广泛差异。迄今为止,与放射外科相关的放射性肿瘤形成和脑血管病变的风险似乎低于分次放射治疗。放射外科术后其他严重并发症的发生率相当低。
虽然手术切除通常是主要治疗方式,但立体定向放射外科为复发性或残留性垂体腺瘤提供了安全有效的治疗方法。在极少数情况下,放射外科可能是垂体腺瘤患者的最佳初始治疗方法。放射外科技术的改进可能会带来更好的治疗效果。